Clostridium difficile infection: Risk factors and potential vaccines

Antibiotics treatment is one of the main factors of risk for developing Clostridium difficile (C. diff) infection, a condition responsible for nearly 500,000 infections and 30,000 deaths each year in the U.S. alone. Dr Joseph Shiloach, Dr Ashish Sharma and their collaborators at the Biotechnology Core Laboratory of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) optimised […]

Read More…

The CEASE approach: A framework to tackle COVID-19 and other microbial threats

The CEASE approach

While the COVID-19 virus continues to spread in many countries worldwide, some researchers are investigating the implications of regularly using antimicrobial products and antibiotics, which could contribute to a concerning phenomenon known as antimicrobial resistance (AMR). Dr Teddie Rahube at Botswana International University of Science and Technology has recently developed CEASE, an approach that addresses some of the challenges associated […]

Read More…

Breaking down the fort: Combatting clinical biofilms

Antibiotic-resistant Acinetobacter baumanii are forming protective layers called biofilms.

Treating bacterial infections can be challenging, even more so when they build a fort. These forts, or ‘biofilms’, form on living and non-living surfaces, such as heart valves, and protect bacteria from immune responses and antibiotics. This can lead to serious, chronic conditions, for instance an infection of the heart’s lining (endocarditis), relapsing infections and increased mortality. To help combat […]

Read More…

Unlocking the chemical secrets of microbial conversations

Dr Matt Traxler of the University of California, Berkeley, is changing the way we study microbes. Gone are the days of thinking about a single species in a pure culture in the lab – Traxler and his team of graduate students and postdocs are developing a version of mass spectrometry which promises to allow single microbial cells, and their interactions […]

Read More…

A new class of antibiotic drugs

a science article about Dr McMaster’s research which focuses on metabolic regulation with an eye toward the development of therapies for unmet medical needs in the infectious and inherited disease spaces.

Finding new classes of antibiotic drugs could not only save human lives, but also greatly reduce the healthcare costs related to tackling bacteria resistant to currently available drugs. Professor Chris McMaster, director of the Cheminformatics Drug Discovery Lab at Dalhousie University in Halifax, Canada, is developing a new class of antibiotics, while trying to overcome the many challenges associated with […]

Read More…

Thank you for expressing interest in joining our mailing list and community. Below you can select how you’d like us to interact with you and we’ll keep you updated with our latest content.

You can change your preferences or unsubscribe by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at audience@researchoutreach.org at any time and if you have any questions about how we handle your data, please review our privacy agreement.

Would you like to learn more about our services?

We use MailChimp as our marketing automation platform. By clicking below to submit this form, you acknowledge that the information you provide will be transferred to MailChimp for processing in accordance with their Privacy Policy and Terms.

Subscribe to our FREE PUBLICATION